Oncolytics Biotech® Announces Upcoming Investor Conferences in September
Oncolytics Biotech (NASDAQ:ONCY), a clinical-stage immunotherapy company focused on developing pelareorep, has announced its participation in two upcoming investor conferences in September 2025. CEO Jared Kelly will engage with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference on September 9-10 and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11.
Both events will take place in New York City, with management conducting one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting the company directly.
Oncolytics Biotech (NASDAQ:ONCY), società clinica nel settore dell’immunoterapia focalizzata sullo sviluppo del pelareorep, ha annunciato la partecipazione a due conferenze per investitori previste a settembre 2025. L’amministratore delegato Jared Kelly incontrerà investitori istituzionali al H.C. Wainwright 27th Annual Global Investment Conference il 9-10 settembre e al Lake Street Capital Markets 9th Annual Best Ideas Growth Conference l’11 settembre.
Entrambi gli eventi si terranno a New York City e il management svolgerà incontri individuali con gli investitori. Le parti interessate possono fissare appuntamenti tramite i rappresentanti delle conferenze o contattando direttamente la società.
Oncolytics Biotech (NASDAQ:ONCY), una compañía en fase clínica de inmunoterapia centrada en el desarrollo de pelareorep, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025. El CEO Jared Kelly se reunirá con inversores institucionales en la H.C. Wainwright 27th Annual Global Investment Conference los días 9 y 10 de septiembre y en la Lake Street Capital Markets 9th Annual Best Ideas Growth Conference el 11 de septiembre.
Ambos eventos se celebrarán en Nueva York y la dirección realizará reuniones individuales con inversores. Los interesados pueden programar citas a través de los representantes de las conferencias o contactando directamente con la empresa.
Oncolytics Biotech (NASDAQ:ONCY)는 펠라레오렙(pelareorep) 개발에 주력하는 임상 단계 면역치료제 회사로, 2025년 9월에 열리는 두 건의 투자자 콘퍼런스에 참가한다고 발표했습니다. CEO 재러드 켈리(Jared Kelly)는 9월 9~10일 H.C. Wainwright 27th Annual Global Investment Conference와 9월 11일 Lake Street Capital Markets 9th Annual Best Ideas Growth Conference에서 기관 투자자들과 만날 예정입니다.
두 행사는 모두 뉴욕시에서 개최되며 경영진은 투자자들과 일대일 미팅을 진행합니다. 관심 있는 분들은 콘퍼런스 담당자를 통해 또는 회사에 직접 연락해 미팅을 예약할 수 있습니다.
Oncolytics Biotech (NASDAQ:ONCY), une société en phase clinique spécialisée en immunothérapie et développant le pelareorep, a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2025. Le PDG Jared Kelly rencontrera des investisseurs institutionnels lors du H.C. Wainwright 27th Annual Global Investment Conference les 9 et 10 septembre, puis au Lake Street Capital Markets 9th Annual Best Ideas Growth Conference le 11 septembre.
Les deux événements se dérouleront à New York City et la direction tiendra des réunions individuelles avec les investisseurs. Les parties intéressées peuvent planifier des rendez‑vous via les représentants des conférences ou en contactant directement la société.
Oncolytics Biotech (NASDAQ:ONCY), ein klinisch arbeitendes Immuntherapie-Unternehmen mit Schwerpunkt auf der Entwicklung von Pelareorep, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt. CEO Jared Kelly wird am H.C. Wainwright 27th Annual Global Investment Conference am 9.–10. September und am Lake Street Capital Markets 9th Annual Best Ideas Growth Conference am 11. September mit institutionellen Investoren zusammentreffen.
Beide Veranstaltungen finden in New York City statt, und das Management wird Einzelgespräche mit Investoren führen. Interessenten können Termine über die Konferenzvertreter oder durch direkte Kontaktaufnahme mit dem Unternehmen vereinbaren.
- None.
- None.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday and Wednesday, September 9 & 10, 2025
Location: Lotte New York Palace Hotel,
Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Date: Thursday, September 11, 2025
Location: The Yale Club,
Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Lake Street Capital Markets representative, or email jpatton@oncolytics.ca.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Logo: https://mma.prnewswire.com/media/2408622/5481159/Oncolytics_Biotech_Inc_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-investor-conferences-in-september-302540829.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When and where will Oncolytics Biotech (ONCY) present at the H.C. Wainwright Conference in 2025?
How can investors schedule meetings with Oncolytics Biotech (ONCY) management at the September 2025 conferences?
What is Oncolytics Biotech's (ONCY) main product in development?
Which investor conferences will Oncolytics Biotech (ONCY) attend in September 2025?
